Agouron Pharmaceuticals, Inc.

Jinjiang Zhu

Min Teng

Sacha Ninkovic

Michael John Bennett

Yong Wang

Suzanne Pritchett Benedict

Fen Wang

Eugene Yuanjin Rui

Yuanjin Rui

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.

Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R, Rand Rare as defined in the specification)pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers.

Growing community of inventors

San Diego, CA, United States of America

Jinjiang Zhu